
|Videos|August 24, 2020
Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy
Author(s)Targeted Oncology
Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















